NASDAQ · Health care

Beta Bionics, Inc. (BBNX)

Beta Bionics, Inc. brought in $119M of revenue over the twelve months to June 30, 2026, up 52.5% from a year earlier. It posted a net loss of $73M. In fiscal 2025 capital spending exceeded operating cash flow by $56.2M. At June 30, 2026 it held $44.3M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on July 29, 2026.

Revenue (last 12 months)

$119M

+52.5% year on year

Net margin

-61.3%

What Beta Bionics, Inc. does

Beta Bionics, Inc. is registered with the SEC under industry code SIC 3841 (Surgical & Medical Instruments & Apparatus). Its shares trade on NASDAQ under the ticker BBNX.

Revenue and profit by year

Revenue

Net income

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Fiscal year	Revenue	Operating income	Net income	Diluted EPS	Free cash flow
2025	$100.3M	-$71.7M	-$73.2M	-$1.81	-$56.2M
2024	$65.1M	-$45.3M	-$54.8M	-$8.60	-$51.7M
2024	$12M	-$35.9M	-$44.1M	-$8.31	-$32.8M

Next report expected around October 5, 2026.

Estimated from its filing rhythm: about 68 days after its last report of July 29, 2026, its usual gap. Not a date the company has announced. See the report calendar

Where BBNX ranks in Health care

Revenue$100.3M

#301 of 523 in Health care · Bottom 43%

Revenue growth+53.9%

#77 of 437 in Health care · Top 17%

Net margin-73.0%

#348 of 447 in Health care · Bottom 22%

Free cash flow margin-56.1%

#314 of 408 in Health care · Bottom 23%

Latest fiscal year of every company in the sector with the figure reported. Revenue is ranked among companies reporting in US dollars; growth and margins among companies with at least 10 million of revenue. Health care

Latest SEC filings

What Beta Bionics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.

September 17, 2026
Other event 8-K
September 17, 2026
Securities offering prospectus 424B5
September 16, 2026
Offering term sheet FWP
September 16, 2026
Securities offering prospectus 424B5
September 15, 2026
Investor disclosure 8-K
August 13, 2026
Passive stake changed SCHEDULE 13G/A
July 29, 2026
Quarterly report 10-Q · period to June 30, 2026
July 29, 2026
Quarterly results 8-K
July 24, 2026
Passive stake (5% or more) SCHEDULE 13G
May 22, 2026
Shareholder vote results 8-K

Recent insider filings (Forms 3, 4 and 144): 10, the latest on September 23, 2026. Insider transactions on SEC

Insider trades

What the people running Beta Bionics, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.

Insiders sold $3M worth of shares in the last 90 days and bought none on the open market. Most of the selling (76%) was pre-planned under Rule 10b5-1 trading plans.

Bought (open market)

last 90 days

Sold

$3M

last 90 days

Net sold

156,604

$3M

Date	Insider	What	Shares	Price	Value	Filing
September 22, 2026	Jones ChristyDirector	Soldpre-planned (10b5-1)	6,430	$23.00	$147.9K	Form 4
September 16, 2026	Hopman MarkChief Commercial Officer	Soldpre-planned (10b5-1)	30,779	$20.13	$619.6K	Form 4
September 16, 2026	Mensinger MikeChief Product Officer	Soldpre-planned (10b5-1)	2,650	$22.00	$58.3K	Form 4
September 14, 2026	Hopman MarkChief Commercial Officer	Soldpre-planned (10b5-1)	775	$15.52	$12K	Form 4
September 9, 2026	Hopman MarkChief Commercial Officer	Soldpre-planned (10b5-1)	35,994	$18.46	$664.6K	Form 4
September 9, 2026	Hopman MarkChief Commercial Officer	Soldpre-planned (10b5-1)	36,870	$18.46	$680.7K	Form 4
September 3, 2026	Saint SeanPresident & CEO, Director	Soldpre-planned (10b5-1)	5,641	$20.08	$113.3K	Form 4
September 2, 2026	Hopman MarkChief Commercial Officer	Sold	5,327	$19.11	$101.8K	Form 4
September 2, 2026	Mensinger MikeChief Product Officer	Sold	4,375	$19.11	$83.6K	Form 4
September 2, 2026	Feider StephenChief Financial Officer	Sold	6,675	$19.11	$127.6K	Form 4
September 2, 2026	Saint SeanPresident & CEO, Director	Sold	16,867	$19.11	$322.4K	Form 4
September 2, 2026	Russell Steven JonChief Medical Officer	Sold	4,221	$19.11	$80.7K	Form 4

All insider filings on SEC.gov · Where insiders are buying across the market

All filings on SEC EDGAR

Questions about BBNX

What does Beta Bionics, Inc. do?

Beta Bionics, Inc. is registered with the SEC under industry code SIC 3841 (Surgical & Medical Instruments & Apparatus). Its shares trade on NASDAQ under the ticker BBNX.

Is Beta Bionics, Inc. profitable?

No. Over the twelve months to June 30, 2026 it reported a net loss of $73M on revenue of $119M.

How much revenue does Beta Bionics, Inc. make?

Over the twelve months to June 30, 2026 Beta Bionics, Inc. reported revenue of $119M. That is 52.5% more than a year earlier.

When did Beta Bionics, Inc. last report?

Its most recent periodic report is the quarterly report (10-Q) filed on July 29, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from September 23, 2026.

Similar companies

Becton Dickinson & Co

BSX

Boston Scientific Corp

BAX

Baxter International Inc

Compare BBNX with

Compare BBNX with any company

Follow BBNX

Get an email when Beta Bionics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.

Follow BBNX: get an email when it files

Where the numbers come from

Financial figures are the values Beta Bionics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.